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Abstract
Cardiac fibroblasts are the most abundant cell in the mammalian heart. While they have been
historically underappreciated in terms of their functional contributions to cardiac development and
physiology, they and their activated form, myofibroblasts, are now known to play key roles in
both development and disease through structural, paracrine, and electrical interactions with
cardiomyocytes. The lack of specific markers for fibroblasts currently convolutes the study of this
dynamic cell lineage, but advances in marker analysis and lineage mapping technologies are
continuously being made. Understanding how to best utilize these tools, both individually and in
combination, will help to elucidate the functional significance of fibroblast-cardiomyocyte
interactions in vivo. Here we review what is currently known about the diverse roles played by
cardiac fibroblasts and myofibroblasts throughout development and periods of injury with the
intent of emphasizing the duality of their nature.
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1. Introduction
Despite being the most numerous cell type in the heart, cardiac fibroblasts (CFs) have
historically been overlooked in the pursuit of understanding cardiac development,
physiology, and disease pathogenesis. It has just been in recent years that their complex and
dynamic interactions with cardiomyocytes have become a focus of investigation; however,
the more we learn about CFs the more we find that the roles they play are highly contextual
and often blur the line between “helpful” and “harmful”. Moreover, although fibroblasts
have typically been considered a uniform cell type with comparable functions regardless of
location within the body, more recent data has demonstrated extensive phenotypic
© 2013 Elsevier Ltd. All rights reserved.
Address correspondence to: Simon J. Conway, 1044 West Walnut Street, Room R4 W402F, Indiana University School of Medicine,
Indianapolis, IN 46202, USA. phone: (317) 278-8780; fax: (317) 278-0138; siconway@iu.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Disclosures
None.
NIH Public Access
Author Manuscript
J Mol Cell Cardiol. Author manuscript; available in PMC 2015 May 01.
Published in final edited form as:
J Mol Cell Cardiol. 2014 May ; 0: 2–8. doi:10.1016/j.yjmcc.2013.11.003.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
heterogeneity among fibroblasts from different tissues and even from the same tissue under
different physiological conditions [1]. Classically, these spindle-shaped cells have been
thought of primarily in terms of how they utilize their extensive endoplasmic reticulum to
secrete the extracellular matrix (ECM) scaffold which mostly serves to support adjacent
cardiomyocytes; too little contribution from CFs and the heart lacks the mechanical strength
to function while over-activation of CFs leads to a scarred, inflexible heart which is all too
often the result of ischemic injury. Similarly, paracrine signals released from CFs can have
paradoxical effects upon the cardiomyocyte lineage. CFs secrete factors that have been
shown in in vitro and ex vivo models to have cardioprotective effects under ischemic
conditions [2, 3]; however, some of these same paracrine factors will ultimately lead to heart
failure via cardiomyocyte hypertrophy and eventual apoptosis [3]. Contributions of CFs to
the electrical milieu of the heart, while less extensively investigated, seem to follow the
same dichotomy. Although we are just beginning to understand how CFs electrically couple
with cardiomyocytes in vitro and starting to translate that work in vivo, already it is
becoming evident that coupling between CFs and cardiomyocytes can be both adaptive, by
allowing for synchronous beating of cardiomyocytes, as well as maladaptive by
predisposing to arrhythmogenesis [4, 5].
Not only do CFs have complex interactions in response to injury (the aspect of their
physiology that we understand the best) but their roles are dynamic throughout in utero and
postnatal development as well as under normal homeostatic conditions. One contributory
factor to the breadth of roles played is the fact that CFs are derived from different progenitor
cells depending on the stage of heart maturation and the cellular context: homeostasis versus
injury. The CFs that you are born with are not necessarily the same as the ones you have in
adulthood and are certainly not the same ones that populate the heart following injury. After
insult, endogenous CFs and a variety of other cell lineages are stimulated to differentiate
into myofibroblasts (an activated form of contractile CF that is highly responsive to growth
factors and inflammatory mediators which is not normally present in the adult heart except
for within the valve leaflets). In many ways, αSmooth muscle actin (αSMA)-positive
myofibroblasts (myoCFs) are the effectors of disease through overcompensation which leads
to the establishment of a fibrogenic milieu. However, what we have yet to fully understand
is whether myoCFs are a distinct subpopulation of CFs responding differently to
environmental cues based upon their origin with some subsets being more pathological than
others. Answering this key question requires an intimate understanding of the signaling
pathways involved in utero as well as following cardiac injury. Significantly, the CF field
has made strides recently; however, the absence of a universal CF marker or method for
lineage mapping, combined with the heterogeneous nature of the collective CF/myoCF
population complicate the experimental design and interpretation of findings in studies
aimed at addressing these clinically relevant questions. The purpose of this review is to
summarize the diverse roles CFs and myoCFs play throughout development and periods of
injury with the intent of emphasizing the duality of their nature (see Fig. 1).
2. Beginning at the beginning
Although diverse origins for CFs have been reported [6–11], the majority of embryonic CFs
are derived from the proepicardial organ [12–18] which gives rise to a migratory cell
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population that eventually covers the heart forming the embryonic epicardium [1, 12, 19].
Some of these cells then undergo epithelial-to-mesenchymal transition (EMT) to become
epicardial-derived cells (EPDCs) which eventually invade the atrial and ventricular walls,
differentiate into CFs, and help establish the compact myocardium [13, 17, 19–21]. The
process of EMT itself, as well as the migration into what will become the compact
myocardium, requires finely tuned interactions between many signaling factors including:
Ets factors, Fibroblast growth factors (FGF), Platelet derived growth factor-β, Sox9, Tbx5,
Thymosin β4, Tcf21 and Transforming growth factors (TGF) [17, 22–26]. Intriguingly,
epicardial cell fate decisions occur in the epicardium before EMT, and the Tcf21
transcription factor appears to be necessary for CF cell fate determination [22]. Fgf10 has
been identified as another key factor and is responsible for regulating the subsequent
migration of CF precursors into the compact myocardium [27]. Interestingly, interruption of
this signaling cascade, at either the ligand or receptor level, resulted in a decreased number
of CFs in the heart as well as a smaller heart size while the opposite was true in a Fgf10
overexpressing model [27]. This study elegantly linked the presence of CFs during
development with the growth and formation of the overall cardiac structure. The exact
timing as to the appearance of CFs is somewhat obscured by the lack of a definitive marker
(discussed later in detail); however, initial embryonic CFs can be detected within the
compact myocardium beginning embryonic day (E) 12.5 [12, 28, 29], a stage at which the
ventricular chambers are enlarging but prior to septation and formation of a definitive 4-
chambered heart[30]. CFs then steadily increase in number through to postnatal day one
[28], forming a relatively uniform myocardial three dimensional network throughout the
heart [31] except around the dense fibro-insulatory sinoatrial node [32]. Once present,
embryonic CFs are thought to be responsible for signaling cardiomyocytes to grow and
proliferate during ventricular compaction which continues until birth [28]. This is
accomplished via β1-integrin signaling stimulated by CF secreted factors such as
Fibronectin, Heparin-binding epidermal growth factor-like growth factor, and Periostin [28].
However, relatively little is known about factors that are essential for differentiation along
the CF lineage [26].
After establishing the embryonic heart’s fibrous skeleton, CFs then take on the role of
facilitating the adaptation of the heart to postnatal stressors. Birth results in a substantial
increase in systolic pressures which could overload and damage the heart if compensatory
mechanisms to increase ventricular thickness and tensile strength were not available. CFs
are thought to play a large role in this process. The number of CFs in the heart doubles
postnatally, and these cells are actively involved in remodeling the ECM to more efficiently
distribute the mechanical stress that is now being applied to the ventricles [33, 34]. This
dynamic period lasts for the first week of life, and at the end of the first month of life, a
mature adult phenotype is observed in the murine heart [19]. Although not expressly
investigated, a similar pattern of morphogenesis is thought to occur in human hearts. As the
connection between developmental and pathological pathways has become more apparent,
studies have begun to focus on the embryonic interactions of CFs and cardiomyocytes and
how they contribute to the overall milieu of the heart. For example, a new cell line of
EPDCs (which differentiate into embryonic CFs) has been derived from mouse embryonic
epicardium and has been purported as a potential model system to study CFs [35]. Not only
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have new sources for cellular models been considered but the actual culturing environment
itself is beginning to be optimized. Fascinatingly, a bioreactor system has been designed for
CF culture to incorporate cyclic stretch, electrical stimuli, and fluid perfusion to better
reconstruct the cardiac niche in vitro [36, 37]. Application of these tools could ostensibly
lead to advancements in our understanding of dynamic CF-cardiomyocyte interactions;
however, the absence of a universal CF marker will still be a major limiting factor in in vivo
studies.
3. Current markers and their limitations
CFs express many genes both embryonically and postnatally. The functional relevance and
temporal expression of these genes have been expertly reviewed elsewhere [12, 38, 39]. A
few of the commonly used CF markers include: Discoidin domain collagen receptor (Ddr) 2,
Fibroblast-specific protein (Fsp) 1, Fibroblast activation protein, Platelet derived growth
factor receptor alpha (Pdgfrα), Periostin, Thy1 cell surface antigen, and Vimentin. No one
marker encompasses the combination of sensitivity and specificity to be definitive, in fact,
there is not even a lineage marker currently in use that is specific to CFs.
The intermediate filament protein Vimentin is the most sensitive out of all the markers (i.e.
all CFs are positive); however, it is similarly expressed by the entire endothelial lineage
making it less useful as a definite CF marker (due to its low specificity). Thy1.1 (or CD90)
is a membrane glycoprotein expressed on the surface of CFs but is also detectable on some
endothelial cells [22]. Similarly, the other markers listed are expressed in various cell types
in addition to fibroblasts, and a few (e.g. the Ddr-2 receptor tyrosine kinase and Fsp-1
filament-binding S100 protein) are only expressed in a small percentage of CFs (reviewed in
[38, 39]) and some may be absent from myoCF scar tissue [40]. Recently, one of the most
widely used markers of CFs (both resting and activated) in the adult heart, Fsp-1 [41], has
been shown to also be expressed within inflammatory leukocytes and vascular cells in
murine infarction and pressure overload-induced fibrosis models convoluting the future use
of this marker [42]. Thus, the absence of comprehensive markers has inhibited our ability to
study the complex interactions between CFs and the surrounding cells in vivo. It may be that
there is no ideal way to identify CFs with a single marker; however, the more we are able to
understand the limitations of the tools that we do have available, the more effectively we
will wield them. Combining multiple markers to more conclusively identify CFs or
understanding which markers are best in a particular context are two steps that are currently
being taken to improve confidence in interpretation of findings. The variable expression of
the most commonly used markers at different stages of development is described in Table 1.
For example, the matricellular protein Periostin is only expressed in a small subset of CFs in
the quiescent adult heart but is robustly up-regulated in response to injury [8, 43–46],
therefore making it a useful marker of activated injury-site fibroblasts [42]. Additionally,
our developmental studies suggest that endogenous Periostin is one of the most reliable
markers of CFs in utero and throughout the early postnatal period [12, 47–49] making it
well suited to developmental and neonatal investigations. Thus, enhancing our
understanding of which markers are useful during the various stages of development or in
response to injury, will better facilitate the studies necessary to elucidate the oft paradoxical
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roles of CFs and how best to shift the balance in favor of repair and optimized cardiac
output.
At present, two of the most promising tools for lineage mapping and genetically
manipulating CFs, and particularly myoCFs, are the Postn-Cre [48] and inducible
Tcf21(iCre) MerCreMer [50] transgenic mouse lines. The Postn-Cre mouse contains a 3.9kb
5’ upstream region of the mouse Periostin genomic DNA driving expression of an
EGFP/Cre fusion expression vector [48], and following intercrossing with the R26R
indicator mice, lacZ expression (indicative of earlier Cre expression) is present within all
non-cardiomyocyte lineages of the fetal and neonatal heart [51–53]. Similar to endogenous
Periostin [12, 54], Postn-cre is also expressed within a few homeostatic CFs but is robustly
expressed within the CFs and myocardial infarct sites following injury [48]. Tcf21(iCre)
mice were generated via targeted insertion and although it is not known how robustly Tcf21-
MerCreMer is expressed following tamoxifen induction within normal or injured adult
hearts, it was recently shown that endogenous Tcf21 is essential for formation of CFs in
utero making this a potentially insightful model particularly during cardiac development
[22].
4. Cardiac Injury
CFs have a dynamic but balanced communication with cardiomyocytes throughout all stages
of development beginning with the genesis of CFs in utero to adulthood wherein they
continue to undergo limited proliferation and regulate ECM turnover; however, all aspects
of these homeostatic interactions are affected by cardiac injury. When the heart experiences
an ischemic insult, there are three instrumental phases of the healing process: inflammatory,
proliferation/granulation, and maturation, each of which directly involves CFs. Following
the initial insult, injured CFs release pro-inflammatory cytokines which are involved in a
feed-forward loop that results in increased proliferation of CFs, re-expression and up-
regulation of many of the markers initially expressed within the embryonic and homeostatic
CFs (see Table 1), and eventually culminates with their differentiation into highly
proliferative migratory myoCFs (“activated” CFs). These myoCFs are exquisitely sensitive
to proliferative signals and secrete more cytokines and growth factors [55]. MyoCFs are not
only derived from resident CFs but have also been reported to originate from epithelial cells,
endothelial cells [41], bone marrow-derived cells (fibrocytes) [8, 9, 19, 56–58], pericytes
[59], as well as smooth muscle cells (Fig 1) (reviewed in [1, 38, 39]). Significantly, it has
recently been proposed that the origin of the developmental precursors may dictate the
pathophysiologic role of CFs [60].
The inflammatory and granulation phases are characterized by myoCFs actively degrading
the ECM while the maturation phase involves reestablishing the ECM by secreting collagens
and other ECM proteins to form scar tissue. From a signaling perspective, this is
accomplished by decreased secretion of pro-inflammatory mediators and an increase in pro-
fibrotic signals such as TGFβ. This “adaptive” fibrosis to maintain the tensile strength and
pressure generating capacity of the heart without loss of cardiomyocytes is termed reactive
fibrosis. However, when myoCFs persist in scar tissue and continue to release inflammatory
signals, this adaptive response becomes maladaptive replacement fibrosis defined by
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cardiomyocyte hypertrophy and necrosis which can lead to progressive heart failure [61–
64]. Throughout this healing process CFs, and their hyperactivated myoCF equivalents, are
involved in the mechanical stability, the signaling health, and the electrical integrity of the
heart. MyoCFs are required for the initial response to injury; however, their continued
presence, particularly in remote non-infarcted areas results in pathological remodeling (Fig.
1) [62]. Understanding which contributions are required to stabilize the heart and at what
point the influence of myoCFs becomes detrimental to the recovery process may allow us to
target myoCFs at a certain time point to improve patient outcomes following a myocardial
infarction. As we learn more about myoCFs, we may even find that inhibiting myoCFs from
a particular origin is more advantageous than others.
4. 1. Mechanics
The most historically recognized role of CFs has been their contribution to secretion,
maintenance, and remodeling of the ECM. While we have since discovered many other
functions, the mechanical contributions of CFs to the heart before and myoCFs after injury
are critical. The rapid differentiation of CFs and other cells into myoCFs and their
subsequent proliferation are required to maintain the structural integrity of the ventricular
walls following injury [65]. MyoCFs accomplish this by regulating the synthesis and
secretion of ECM components (collagens, fibronectin and laminins) as well as ECM-
regulatory and remodeling molecules such as matricellular proteins and metalloproteinases
(MMPs) [47, 66, 67]. If the mechanical strength of the infarct is not maintained, the
ventricle may rupture; however, if excess collagen is laid down, then the fibrotic
environment leads to further cardiomyocyte death and impedes the contractile function of
the heart. This was elegantly demonstrated in vivo by Takeda and colleagues [48], wherein a
conditional knockout of the Klf5 transcription factor, crucial for tissue remodeling, was
shown to exert its effects via myoCFs. When Klf5 was deleted from CFs but not
cardiomyocytes using the Postn-Cre, low-intensity transverse aortic constriction resulted in
decreased hypertrophy of cardiomyocytes and diminished overall fibrosis. Thus the
conditional knockouts fared better than their littermate controls; however, when the same
model was subjected to high-intensity transverse aortic constriction, the CF-specific
knockouts could not endure the acute stress of the injury and died at much higher rates than
controls [48]. This was concluded to be a CF-specific response as deletion of Klf5 with a
cardiomyocyte-specific Cre did not affect the hypertrophic response to injury. Other mouse
models have yielded similar results; as mice lacking several matricellular proteins (models
of Periostin null, SPARC null and TSP-2 null mice have all been studied) showed increased
vulnerability to cardiac rupture following infarct due to inadequate tensile strength of the
ventricle (reviewed [68]). From these studies, it is evident that CFs and their myoCF
derivatives are necessary to exert a positive mechanical influence on the ventricle in times of
acute injury; however, after this initial need is met, it may be possible to modulate myoCFs
to prevent excessive fibrosis by targeting factors such as Klf5 or matricellular proteins.
Continuing work in this area will serve to elucidate not only which targets would be most
efficacious, but also when would be the most appropriate time for intervention in order to
maximize the benefit to patients.
Lajiness and Conway Page 6
J Mol Cell Cardiol. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4. 2. Signaling
CFs and cardiomyocytes have an extensive, reciprocal communication via several signaling
molecules, and the intensity of these signals is only increased following injury. CFs and
myoCFs to an even larger extent secrete proinflammatory cytokines such as IL-1β, IL-6,
TNFα, and TGFβ which directly leads to cardiomyocyte hypertrophy [61–64].
Cardiomyocytes also release these same factors which signal CFs to proliferate, differentiate
into myoCFs, and increase synthesis of ECM components. TGFβ1, in particular, is thought
to be sufficient for CF differentiation into myoCFs [1, 66, 67, 69, 70]. This pro-
inflammatory, pro-fibrotic environment is initially adaptive as factors secreted from CFs and
myoCFs protect the injured myocardium, and while they may lead to temporary cellular
hypertrophy, they promote cardiomyocyte survival [2]. TGFβ1, for example, has been
shown to decrease cardiomyocyte death when delivered exogenously during the reperfusion
stage of an ischemia-reperfusion rat model [67]. Similarly, in vitro and ex vivo Langendoff
studies have suggested a role for non-cardiomyocytes, especially CFs, in mitigating
cardiomyocyte injury following hypoxia and ischemia-reperfusion exposure via secretion of
unknown cardioprotective substance/s [2]. In addition to pro-inflammatory cytokines,
myoCFs also secrete Angiotensin II, Endothelin-1, Natriuretic peptides, and VEGF to
facilitate the wound healing process [64]. Ideally, this intense signaling environment is self-
limiting; however, when the protective feedback mechanisms fail and levels of these
cytokines and signaling molecules become chronically elevated, fibrosis, hypertrophy, and
heart failure results [3, 61–64]. Considering the current challenges in CF-specific targeting
(especially prior to myoCF activation) and that other heart lineages can produce the same
mediators, this concept has proved difficult to verify in vivo.
As with the mechanical contributions of CFs, it is evident that CF signaling to
cardiomyocytes is essential, but if not properly balanced this can lead to pathology, further
underscoring the dichotomy of CF/myoCF effects on the heart and complicating therapeutic
intervention. CFs are indeed a viable target for modulating the fibrotic outcome of a
myocardial infarction as indicated by work attributing desirable remodeling changes in
response to drugs that happen to have off-target inhibitory effects on CFs and myoCFs.
Angiotensin-converting-enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs),
beta blockers, Statins, and Thiazolidinediones (TZDs) have all been shown to have positive
effects on ECM remodeling either by inhibiting CF proliferation and differentiation to
myoCFs or by deterring the expression of cytokines and growth factors (reviewed [64]).
Mechanistically, the majority of this work has been borne out through in vitro
experimentation; however, clinical studies and animal models have begun to elucidate both
positive and detrimental aspects of each of these pharmacological interventions. The
complexity of in vivo models makes delineating direct effects more difficult, but with a
stronger background in the basic science regulating the interaction of CFs, myoCFs,
cardiomyocytes, and the overall condition of the heart, interventions may be designed and
optimized to improve the quality of care for patients with cardiac disease.
4. 3. Electrical communication
It has only been recently that the importance of electrical communication between CFs and
cardiomyocytes has been reported. CFs have always been described as electrically inert and
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therefore have often been presumed to play no role in the cardiac electrical milieu. However
CFs do electrically couple to cardiomyocytes [71] and this coupling has been shown in vitro
to alter the electrical properties of cardiomyocytes including conduction, resting potential,
repolarization, and excitability [4] as well as to synchronize contractions between individual
cardiomyocytes [5]. CFs express connexins (Cx) 43, 45, and possibly Cx40, although not all
studies agree on the latter. As Cx43 is the primary connexin expressed in cardiomyocytes, it
has been the most extensively studied and is considered the most functionally relevant [72–
74]. Following cardiac injury, cardiomyocytes downregulate Cx43 while CFs/myoCFs
increase its expression in response to TGFβ [75]. It has been speculated that cardiomyocytes
decrease Cx43 expression to contain the transmission of pro-inflammatory signals between
neighboring cardiomyocytes whereas CFs increase connexin expression to bolster electrical
and metabolic coupling between neighboring cardiomyocytes and facilitate contractile
function of the heart [75]. The altered Cx43 expression patterns have multifactorial effects.
From a purely electrical standpoint, although CFs are unexcitable, they can significantly
alter action potential durations and upstroke velocity in adjoining cardiomyocytes [76]. The
coupling of cardiomyocytes to CFs can allow for electrical transmission across an infarcted
area of the heart which is essential for the heart to continue to beat synchronously; however,
it can also predispose to arrhythmogenesis [4, 75–83]. Altering Cx43 expression has been
shown to modulate intercellular coupling [72, 84], and the risk of post-infarction ventricular
tachycardia is significantly reduced when electrical coupling is enhanced by engrafting
Cx43 expressing myocytes in the heart [82]. Gene therapy with dominant negative mutants
of Cx43 has been investigated as a method of decreasing coupling in the context of atrial
fibrillation and ventricular tachycardia. So, it seems as if both enhancing as well as
diminishing CF coupling to cardiomyocytes could be applicable in different clinical settings.
Interestingly, the effect of CF-cardiomyocyte coupling on the electrical parameters of the
heart is extremely density dependent; increased coupling tends to increase conduction
velocity at low fibroblast densities [61, 85, 86] but at high densities of CFs conduction
velocity is slowed to the point of occasionally resulting in conduction failure [61, 76, 85–
88]. It is evident that there are many nuances and intricacies that need to be examined before
these types of interventions could be clinically useful; however, the potential for medical
advancement via modulating CF-cardiomyocyte interactions is promising.
Combined, a number of studies have demonstrated that CFs can interact with
cardiomyocytes through mechanical, chemical, and electrical means and that each of these
components holds therapeutic promise; however, none of these interactions are independent
of any other. Paracrine secretion of signaling factors from CFs and myoCFs not only
influences cardiomyocytes, but can also alter ECM composition and electrical conductivity
[72, 89]. Similarly, interfering with electrical coupling by diminishing Cx43 expression
leads to a decrease in IL-6 secretion and overall fibroblast proliferation while increasing the
secretion of TNFα, indicating the presence of compensatory signaling responses to changes
in intercellular coupling [72, 90]. TNFα secretion can, in turn, predispose cardiomyocytes to
apoptosis during hypertrophy which can drastically affect the mechanical stability of the
heart [90]. CFs and myoCFs respond to mechanical stimuli such as stretch and have
mechanisms to alter their proliferation or migration profiles in response to these stimuli.
However, it should be noted that a number of the studies that revealed paracrine interactions
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and electrophysiological communication were mostly based on the use of neonatal
ventricular cardiomyocytes and were conducted without differentiating between myoCFs
and CFs, thus future in vivo approaches with adult myocytes and more careful examination
of the state of the CFs are required to determine if these studies can be translated into adults
[65]. Essentially, it is thought that the mechanical, chemical, and electrical contributions of
CFs are interrelated and when the balance of one aspect is skewed, the homeostasis and
overall health of the heart is jeopardized. Understanding these intricacies and how these
relationships evolve from the normal developmental state to the pathological state in vivo
will help us to more accurately describe the origins of disease and to more effectively go
about designing therapeutic interventions.
5. Conclusions
CFs comprise an essential and dynamic cell population in the mammalian heart. They are
crucially involved in both development and the response to injury. CFs establish and
maintain the mechanical, biochemical, and electrical environment of the heart through
intricately balanced and interdependent interactions with cardiomyocytes. Cardiac injury
disrupts this balance by shifting the heart into a pro-inflammatory, pro-fibrotic state. This
adaptive response serves to augment wound healing but if homeostasis is not regained, then
the heart deteriorates toward heart failure. MyoCFs are mediators of both the adaptive and
maladaptive components of this reaction. By furthering our understanding of the beneficial
and deleterious roles of CFs and myoCFs and how these roles are related to each other in
development as well as disease, we may be able to design interventions to prevent the
progression of heart failure by modulating these effects. It is widely acknowledged that CFs
and myoCFs are prime targets for treatments of cardiac disease; however, our limited
understanding of the details of the various roles that these cell populations play as well as
how those various roles are intertwined in vivo hinders the design and application of
potential therapies. As the response of CFs to any particular stimuli is extremely contextual,
in vitro studies are limited because the microenvironment of the heart is dynamic
particularly following an insult and cannot be reproduced in culture. Yet, most of what we
know about CFs has been derived from in vitro studies. As better in vivo approaches are
developed, aided by more sophisticated methods of identifying CFs either by lineage
mapping strategies, novel biological markers, or the combination of markers currently in
use; we will be able to investigate the roles of CFs from their origin in utero to their adult
state. And perhaps in comprehending the inherent duality of CFs and myoCFs, we may be
able to develop focused therapeutic interventions that can accommodate a more
comprehensive understanding of the interactions between CFs, myoCFs, and
cardiomyocytes to proactively abate heart failure.
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Highlights
• There is no single lineage marker currently in use that is specific for CFs.
• CFs transmit structural, paracrine, and electrical signals to cardiomyocytes
• Differentiating between myoCFs and CFs is key to develop effective
interventions
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Figure 1. MyoCFs originate from a variety of sources and exhibit both adaptive as well as detrimental effects upon the healing process
MyoCFs can be derived from the endothelium and epithelium via mesenchymal transition (EMT and EndMT), as well as from
perivascular cells, circulating monocytes and bone marrow-derived progenitors, particularly in the context of injury. Resident
CFs also contribute to this pool by undergoing a low level of turnover. The resultant myoCFs are then involved in both
constructive (black text) as well as harmful (red text) effects on the myocardium of the injured heart.
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Table 1
Commonly utilized fibroblast makers are listed along with their relative expression levels at varying
developmental and/or injury states.
Developmentally
expressed
markers
Adult CF
resting
markers
Myofibroblast
markers
References
Thymus cell antigen-1 (Thy1) ++ ++ ++ [28, 91]
Vimentin ++ ++ ++ [92, 93]
Periostin ++ +/− ++ [52, 53, 94]
Ddr2 ++ + ++ [1, 32, 95, 96]
Fibroblast-specific protein-1 (FSP1) ++ +/− +++ [39, 97, 98]
αSmooth muscle actin +/− +/− +++ [47, 66, 67]
Platelet-derived growth factor receptor-β (PDGFRβ) ++ ++ ++ [97, 99]
Fibroblast activation protein ++ ++ ++ [1, 100]
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